about
Epidermal growth factor receptor inhibitors: coming of ageNonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health studyPhase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsPhase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic CancerPET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolitesRisks and benefits of phase 1 clinical trial participation.Participation of the elderly population in clinical trials: barriers and solutions.Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer.Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?Importins and exportins as therapeutic targets in cancer.Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.Role of Biologics in First-Line Treatment of Colorectal Cancer.Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor.Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis.Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia.Rho GTPase effectors and NAD metabolism in cancer immune suppression.Contemporary Management of Localized Resectable Pancreatic Cancer.A pilot study of sunitinib malate in patients with metastatic uveal melanoma.Novel immunotherapy strategies for hepatobiliary cancersNovel targeted treatment options for advanced cholangiocarcinomaPrognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experiencePhase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancerLocal excision for patients with stage I anal canal squamous cell carcinoma can be curativeClinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.Fatal pulmonary toxicity after a single dose of cyclophosphamideTumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccineUnexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptorCarboplatin and paclitaxel treatment is effective in advanced anal cancerClinical trials and drug developmentA phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptomsSurvival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the PancreasEvaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
P50
Q27030769-46F88401-0BD7-4105-8DB8-A88E25F4EAB6Q28200646-449F009C-4482-448A-AD8A-8E202B974DE4Q33424008-5F16D23D-82ED-4381-8B16-34F78945DDCEQ33425196-A4F6A7D4-29B2-4D56-AC2C-AE58E139C072Q33430367-B6EF68F4-5C89-4A13-9A87-DA22FABA977FQ33439682-14C88374-B05B-4EAB-856B-F0547B370935Q35953756-A5DC6AAE-31B0-44F1-910D-2EC0D34A2986Q36078792-B09D4B94-7CAA-4638-8FF0-86A0DE8BEAF6Q36745224-4157CD9B-483F-4E45-958F-085B6F9620F5Q37082597-22D0782B-C24C-4493-AD84-2BF031DAE934Q38222465-C3C92B3E-C9D1-4C3F-B761-C2CC1C14D675Q38222467-1541FAA5-4483-4BFB-B1FF-422EC6F9D8EAQ38410725-226CE12C-0AFE-43B9-AA5E-D1FF715FA3E1Q38505174-930428A1-EA48-4DF5-AE01-681928332A5FQ38611666-526F5BCD-A0AB-4C82-A3D1-B1367E51CF79Q38817412-8495E83A-F786-4509-A95C-5E6AF601082EQ38959172-BF556763-E45E-482E-8D15-D411F768B7CCQ38983881-47E0EECA-37AA-41AA-869C-D8B1E0F2F40CQ39036391-96A45E31-734D-42F2-A356-931DE1CC5595Q39080594-6CA50CDB-5798-4362-AFD3-A7F5954E66DCQ40077156-24328FAB-69F8-4109-A814-EB09A242CD49Q40368139-F4471778-417B-48DA-9560-6C1A66B04913Q42920639-C397FBCA-6B45-4C84-9DD5-4DA44DA683E4Q45974765-89707C3A-BD95-46CD-90D6-A21AB0EBC4DDQ47716584-029C5174-426E-419B-8C89-4126B79C348AQ54474130-5FC888AA-7915-4B8F-AC0F-79FEC603D08DQ56889483-B0376F55-910E-446F-977E-15B75A5D1D06Q57109603-5EB06551-EFD2-4641-8C02-1CC74313CB52Q57119905-2F2268D8-1BEA-4C67-A9E7-B1B964BC6355Q57289388-3B5B5C8E-62D2-40D1-82C3-3F330F981B7AQ64094440-45CB8455-718F-4FDB-8D17-2D2F8CDB246EQ64955459-4DB692CD-A845-4A9A-AB0D-5D8EFCCF7C40Q80024405-6C5776CD-EF82-490F-B8C6-6F8BF5E84327Q83967473-A9BB38B7-1315-4573-96C5-3952AC770E16Q86836445-894EC39A-4F8A-4C76-8957-2BE328239BBAQ87381563-FC4D26E5-06E5-4346-AD09-519A8ADE0809Q88134149-07449460-A8C3-4E5C-9FC5-7DA05DFE3099Q90135293-1C537EB5-E6A3-4F95-B48B-9B0524FD999AQ90413448-CCD72AAB-703D-44DF-B309-3E0A09F88983Q91828927-481D41A8-8CF4-4276-AB73-44CE2AE8B8C2
P50
description
researcher ORCID ID=0000-0002-1111-8333
@en
wetenschapper
@nl
name
Amit Mahipal
@en
Amit Mahipal
@nl
type
label
Amit Mahipal
@en
Amit Mahipal
@nl
prefLabel
Amit Mahipal
@en
Amit Mahipal
@nl
P106
P108
P31
P496
0000-0002-1111-8333